

- 1 Behavior-change interventions to improve antimicrobial stewardship in human health, animal health, and
- 2 livestock agriculture: A systematic review
- 3 Jessica Craig^{1*}, Rachel Sadoff², Sarah Bennett³, Felix Bahati^{4,5}, Wendy Beauvais¹
- 4 ¹Purdue University, College of Veterinary Medicine, Department of Comparative Pathobiology, Indiana,
- 5 47906 USA
- 6 ²Columbia University, Mailman School of Public Health, New York, USA
- 7 ³King's College London, London, UK
- 8 ⁴KEMRI Wellcome Trust Research Programme, Health Services Research Unit, Nairobi, Kenya
- 9 ⁵Jomo Kenyatta University of Agriculture and Technology, College of Health Sciences, Department of
- 10 Environmental Health and Disease Control, Nairobi, Kenya
- 11 *Corresponding author – craig119@purdue.edu

12 **Abstract**

13 Antimicrobial resistance (AMR) is an economic, food security, and global health threat that is
14 driven by a multitude of factors including the overuse and misuse of antimicrobials in the human health,
15 animal health, and agriculture sectors. Given the rapid emergence and spread of AMR and the relative
16 lack of development of new antimicrobials or alternative therapies, there is a need to develop and
17 implement non-pharmaceutical AMR mitigation policies and interventions that improve antimicrobial
18 stewardship (AMS) practices across all sectors where antimicrobials are used. We conducted a systematic
19 literature review per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines
20 to identify peer-reviewed studies that described behavior-change interventions that aimed to improve
21 AMS and/or reduce inappropriate antimicrobial use in the human health, animal health, and livestock
22 agriculture stakeholders. We identified 301 total publications – 11 in the animal health sector and 290 in
23 the human health sector – and assessed these interventions using metrics across five thematic areas- (1)
24 antimicrobial use (AMU), (2) adherence to clinical guidelines, (3) AMS, (4) AMR, and (5) clinical
25 outcomes. The lack of studies in the animal health sector precluded a meta-analysis. Among studies in the
26 human health sector, 35.7% reported significant ($p < 0.05$) pre- to post-intervention decreases in AMU,
27 73.7% reported significant improvements in adherence of antimicrobial therapies to clinical guidelines,
28 45% demonstrated significant improvements in AMS practices, 45.5% reported significant decreases in
29 the proportion of isolates that were resistant to antibiotics or the proportion of patients with drug-resistant
30 infections across 17 antimicrobial-organism combinations, and few studies reported statistically
31 significant changes in clinical outcomes. We did not identify any overarching intervention type nor
32 characteristics associated with successful improvement in AMS, AMR, AMU, adherence, nor clinical
33 outcomes.

34 Introduction

35 Antimicrobial resistance (AMR) is an economic, food security, and global health threat (1–3).
36 Globally, there were an estimated 4.95 million and 1.27 million human deaths associated with or directly
37 attributable to drug-resistant bacterial infections, respectively, in 2019 (4). The Centers for Disease
38 Control and Prevention estimates that the annual cost to treat hospital- and community-acquired drug-
39 resistant bacterial infections in the US alone is \$4.6 billion due to prolonged hospital stays, more complex
40 healthcare needs, and treatment with second- and third-line antimicrobial therapies (5). In addition to the
41 human health burden, AMR among pathogens affecting animals has adverse animal welfare impacts and
42 imposes additional treatment costs on animal owners, ultimately leading to increased costs of food
43 production. The emergence of new drug-resistant pathogens may also hinder global food and animal trade
44 (3,6). Researchers estimate that AMR may cause a 7.5 percent decline in global livestock production by
45 2050 (7).

46 Drug resistance is driven by a multitude of factors including the overuse and misuse of
47 antimicrobials in the human health, animal health, and agriculture sectors. Although antimicrobial use
48 (AMU) and consumption (AMC) surveillance is limited in the human and animal health sectors, available
49 evidence demonstrates that AMU is increasing globally. Analysis of AMC rates, approximated from data
50 on national-level antimicrobial sales data, indicated a 39% increase in per capita AMC in the human
51 health sector between 2000 and 2015, rising from 11.3 to 15.7 daily defined doses per 1,000 people per
52 day (DIDs) (8). Concerningly, the use of World Health Organization-designated “Watch” antibiotics has
53 increased faster than “Access” antibiotics. Between 2000 and 2015, there was a 90.9% increase in the
54 global per capita consumption of “Watch” antibiotics, from 3.3 to 6.3, compared to a 26.2% increase in
55 the global per capita consumption “Access” antibiotics which rose from 8.4 to 10.6 DIDs in the same
56 period (9). Previous studies show clinically inappropriate AMU rates as high as 55% in South Africa,
57 88% in Pakistan, and 61% in China in the human health sector; however, emerging evidence suggests
58 there is significant heterogeneity in AMU practices across countries and clinical settings (10–13). Best

59 available evidence suggests that AMU in the animal health sector is rising as the global demand for
60 animal products increases (14). In 2017, there were an estimated 93,309 tons (95% confidence interval
61 [CI]: 64,443-149,886) of antimicrobials sold for use in chicken, cattle, and pig systems across 41
62 countries. In the same year, AMC in the aquaculture sector was estimated at 10,259 tons across six fish
63 species in 33 countries (15). By 2030, AMU is projected to rise to 104,079 tons among chicken, cattle,
64 and pigs and to 13,600 tons among fish (14,15).

65 Concerningly, the emergence and evolution of drug-resistant microorganisms is outpacing the
66 development of new antimicrobial agents. In the past 50 years, no new antimicrobial agents active against
67 gram-negative bacteria have been brought to market, and only 5 of the 20 major global pharmaceutical
68 companies are engaged in antimicrobial research and development (R&D) (16). Investment in
69 antimicrobial R&D is not considered lucrative given the challenges in antimicrobial discovery, rapid
70 introduction of generic formulations, and the speed at which microorganisms develop resistance to
71 antimicrobials. Moreover, new antimicrobials are likely to be reserved for special or emergency use to
72 preserve their efficacy; therefore, there would paradoxically be less demand for these drugs.

73 While AMR poses an increasing public health threat, the number of deaths that could have been
74 prevented by improving access to antimicrobials, about 5.7 million in low- and middle-income countries
75 (LMICs), exceeds the morbidity and mortality burden from AMR indicating that access to clinically
76 appropriate antimicrobials for the treatment of infectious diseases remains a critical issue (16).

77 Given the health and economic impacts of AMR, challenges around access to appropriate
78 antimicrobial therapies, and the lack of antimicrobial R&D, there is an urgent need to develop and
79 implement impactful non-pharmaceutical AMR mitigation policies and interventions that improve
80 antimicrobial stewardship (AMS) practices in the human health, animal health, and agriculture sectors.
81 There is a growing body of literature describing such non-pharmaceutical AMS interventions which
82 include education, training, and health information campaigns to improve awareness and knowledge
83 among technical stakeholders and the public; installing AMS committees in healthcare facilities to
84 approve and/or review prescription practices; and developing and implementing standard clinical

85 treatment guidelines or clinical treatment algorithms which provide clinicians with an evidence-based
86 resource to guide clinical decision making around AMU and prescription (17–19). Despite this emerging
87 evidence, there remains no consensus on what constitutes the most impactful or cost-effective AMS
88 practices across various sectors and settings. Therefore, the purpose of this study was to conduct a
89 systematic literature review and meta-analysis to identify behavior-change interventions aimed at
90 improving AMS and AMU across the human health, animal health, and agriculture sectors to identify
91 gaps in the evidence base or to describe trends towards best AMS practices in various resource and
92 income settings.

93 **Materials and Methods**

94 This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic
95 Reviews and Meta-Analyses (PRISMA) guidelines (20). We searched PubMed, Web of Science, Embase,
96 Centre for Agriculture and Bioscience International (CABI), and the Cochrane Database of Systematic
97 Reviews for peer-reviewed studies that described behavior-change interventions that aimed to improve
98 AMS and/or reduce inappropriate AMU or AMC among human health, animal health, and livestock
99 agriculture stakeholders including but not limited to health providers, patients, farmers, or animal owners
100 (21–25). Two searches were conducted; the first on 15 June 2021 identified studies published prior to 15
101 June 2021 and a second search conducted on 31 August 2022 identified studies published between 15
102 June 2021 and 31 August 2022 (inclusive). The following search string was used to search the title and
103 abstracts of published entries within each database: (intervention OR trial) AND (antimicrobial” OR
104 antibiotic) AND (use OR stewardship OR consumption OR prescription).

105 Two researchers independently screened returned entries for eligibility in a two-step process: a
106 review of the title and abstract followed by full-text review, according to the following criteria: (1) Only
107 scientific articles published in peer-reviewed journals were included; pre-prints, course completion papers
108 or theses, and internal reports or policy briefs were excluded. (2) Papers published in any language and
109 written on interventions conducted in any country were included. (3) All study types including

110 randomized controlled trials and observational studies (including pre/post study designs) were
111 included. Review articles were screened for additional relevant studies. (4) Studies were included if they
112 reported on at least one outcome which fell into three general categories: (a) AMU or AMC; (b)
113 adherence/compliance of antimicrobial therapy to facility, national, or international clinical treatment
114 guidelines; and (c) rates of specific stewardship practices such as the intravenous to oral therapy
115 conversion rates, frequency of obtaining specimen cultures for pathogen identification and/or
116 antimicrobial susceptibility tests. For studies that reported on at least one primary outcome, we also
117 extracted data for this study's secondary outcomes which included the incidence or prevalence of drug-
118 resistant infections; length of stay in the healthcare facility or specific unit (such as intensive care); health
119 outcomes such as patient/animal mortality or rehospitalization rates; and the economic or cost impact of
120 interventions. (5) Non-relevant papers that did not describe interventions aimed at changing behaviors to
121 optimize AMU, AMC, or AMS in the human health, animal health, or livestock agriculture sectors or
122 those that did not report on our primary outcomes of interest were excluded. Therefore, studies such as
123 those that reported solely on changes in knowledge, attitudes, and perceptions regarding AMR or AMU
124 were excluded as were studies that assessed drug or drug regimen efficacy. (6) Studies were also excluded
125 if the full text was unavailable or unobtainable, if results and statistics were not presented numerically
126 (such as only presented graphically), or if insufficient data was reported to conduct statistical analyses
127 such as to calculate odds ratios or risk ratios or conduct t-tests or Chi-square tests. At each stage, two
128 reviewers independently screened entries for eligibility, identified discrepancies, and re-evaluated articles
129 until a consensus was reached. Duplicates were identified when results from each search were combined
130 into a single database.

131 Data extraction was conducted by one researcher (JC, SB, FB) and reviewed by a second (JC, SB,
132 and FB); data was compiled using Microsoft Excel software. We used a standardized spreadsheet (S4 file)
133 to extract data from each publication that met our inclusion criteria, including the publication year,
134 country and setting on the intervention, type of evaluation, type of study, description of intervention,
135 intervention start and end date and duration, total sample size and unit of sample size, the study's

136 outcome, and all relevant numerical data reported. The income classification of the country where the
137 intervention occurred, per the World Bank's 2021 classification, was also extracted (26). We classified
138 studies as being either single or multi-center and we classified interventions either single or bundled
139 (meaning more than one type of intervention occurred), based on the publication. Duration of intervention
140 was computed, if not provided in the study, using the intervention start and end dates.

141 For the meta-analysis, we created syntheses based on three criteria: type of statistic reported,
142 study type, and outcome variables. First, studies were categorized by type of statistic (rates or
143 proportions) reported. Then studies were categorized by study type or data analysis/reporting
144 methodology. These categories included: pre/post observational studies; randomized or non-randomized
145 control trials (RCTs) that compared a control arm to an experimental/intervention arm; randomized or
146 non-randomized control trials that compared one intervention arm to another intervention arm; and time
147 series studies. We then categorized the studies by outcome. For all studies, odds ratio, rate ratio, 95%
148 confidence interval, chi-square statistic, Wilcoxon signed-rank test, and independent or dependent t-test
149 statistics were calculated, as relevant, to compare the study arms or pre- to post-intervention changes
150 according to the study outcomes. Bivariate analyses and linear and logistic regression analyses were
151 conducted across studies to identify trends in intervention success in various settings. For logistic
152 regression analyses for the pre- to post-intervention studies, a categorical variable was created with 3
153 categories indicating if there was a significant increase, significant decrease, or no statistically significant
154 change in pre- to post-intervention outcomes. Backwards stepwise elimination process based on
155 likelihood ratio tests was used to build final regression models. The Quality Assessment Tool for
156 Quantitative Studies was used to assess study quality and risk of bias (27). For the quality assessment,
157 each study was independently reviewed by two researchers with a third to resolve disputes and compute a
158 consensus quality score.

159 **Results**

160 Our review returned a total of 154,106 publications of which 4,893 were duplicates; 148,639
161 were determined to be irrelevant based on the title and abstract review; and 36 were identified as review
162 articles. Following full-text review, a total of 301 publications – 11 in the animal health sector and 290 in
163 the human health sector (S1 and S2 files) – met the study’s inclusion criteria and underwent data
164 extraction (Fig 1). Per the Quality Assessment Tool for Quantitative Studies, 4 of 11 studies that
165 described interventions in the animal health or agriculture sectors (36.4%) were determined to have strong
166 overall quality ratings, 3 (27.3%) had moderate quality ratings, and 4 (36.4%) had weak quality ratings
167 while 129 of the 290 studies (44.5%) that described interventions in the human health sector were
168 determined to have strong overall quality, 115 (39.7%) had moderate overall quality, and 46 (15.9%) had
169 low overall quality scores (S3 file). A common reason for low quality scores was a high risk of selection
170 bias or failing to control for potential cofounders.

171 **Fig 1. Flow diagram of systematic literature review describing behavior change interventions to**
172 **improve antimicrobial use and stewardship in the animal and human health sectors.**

173 **Animal health and agriculture sectors**

174 Only 11 studies conducted in the animal health or agriculture sector met our study’s inclusion
175 criteria, and given heterogeneity across the study types, outcomes, and types of statistics reported, a meta-
176 analysis was not possible. Seven of the studies (63.6%) assessed the impact of interventions among food-
177 producing animals including swine (n=3), poultry (n=1), dairy cows (n=2), and calves (n=1) (28–34).
178 Four studies (36.4%) assessed interventions in companion animals (35–38). Year of study publication
179 ranged from 2014 to 2021. Across the 11 studies, 8 countries were represented (Germany, Sweden,
180 Netherlands, Belgium, France, Switzerland, the United Kingdom, and Vietnam). Interventions ranged
181 from 5 months in duration to 5 years. Five studies (45.5%) implemented bundled interventions while the
182 remaining 7 studies (63.6%) tested single interventions. Four studies (36.4%) implemented online AMS
183 tools that either provided guidance on AMU and AMS or restricted antimicrobial prescriptions. Other
184 interventions included veterinary guidance on husbandry, biosecurity, or AMU; educational programs;

185 review and feedback of AMU; and programs to implement infection prevention and control measures.
186 Overall AMU decreased significantly (p value < 0.05) for all but one study which implemented an online
187 stewardship tool among calf farmers in Switzerland (29). Three studies assessed pre- to post-intervention
188 changes in animal health status and productivity and documented either no change or an improvement in
189 mortality, animal weight gain, or feed conversion ratio associated with the intervention (28,32,33). One
190 study that implemented a voluntary AMS program among pig farmers in France documented a 90%
191 reduction in cephalosporin usage between 2010 and 2016 and demonstrated a reduction in drug-resistance
192 among commensal and pathogenic *Escherichia coli* isolates sampled during the same period (31).

193 **Human health sector**

194 Of the 290 studies that assessed behavior-change interventions in the human health sector, 40
195 (13.7%) were RCTs, 237 (81.7%) were pre/post observational studies, and the remaining 13 (4.5%)
196 followed alternative study designs such as historical cohort study. Ninety-seven studies (33.4%) were
197 retrospective, 129 (44.5%) were prospective, 49 studies (16.9%) utilized both retrospective and
198 prospective evaluations, and the remaining studies did not specify the evaluation type utilized to assess
199 the intervention. Year of publication ranged from 2001 ($n=2$) to 2021 ($n=44$). Studies were most
200 commonly conducted in high-income countries ($n=228$ studies, 78.6%) with 32, 21, and 3 studies (11.0,
201 7.2, 1.0%, respectively) conducted in upper-middle, lower-middle, and low-income countries,
202 respectively. A total of 49 countries were represented across the studies that met our inclusion criteria;
203 USA ($n=110$ studies), Canada ($n=16$), Japan ($n=15$), Spain ($n=15$), China ($n=12$), and Italy ($n=10$) were
204 the most represented. Academic/teaching hospitals or tertiary care facilities were the most common
205 setting for intervention implementation.

206 Given the smaller number of studies that utilized RCTs designs and the heterogeneity across data
207 and outcomes, a meta-analysis of RCTs was not possible; therefore, we focus our meta-analysis on
208 interventions evaluated through pre/post observational study designs.

209 **Theme 1: Antimicrobial use**

210 Of 290 studies that described interventions in the human healthcare setting and met our eligibility
211 criteria, we extracted AMU data, quantified as a proportion of *patients* who received an antimicrobial
212 before and after the study intervention, from 42 studies (Fig 2). The denominator (i.e. *patients*) was
213 defined differently in each study e.g. patients presenting at a primary healthcare facility, patients in a
214 long-term care facility. Amongst the 15 of 42 studies (35.7%) that found a statistically significant (p value
215 <0.05) pre- to post-intervention decrease in AMU; the average decrease in the proportion of patients
216 receiving various antimicrobial agents or classes was 10.4% (Standard deviation [SD]: 16.6) and the
217 range was 3.1 to 58%. Four of these studies described interventions in lower-middle-income countries
218 (Bangladesh, India, $n=2$, Iran), two in upper-middle-income countries (China, Malaysia), and 9 in high-
219 income countries (Finland, Hong Kong, Netherlands, Spain, UK, USA, $n=4$). The clinical settings
220 involved in these interventions included a veteran's hospital, a university dentistry practice, a long-term
221 care facility, a pediatric hospital, primary healthcare or community clinics ($n=4$ studies), secondary or
222 tertiary hospitals ($n=5$ studies). Across these 15 studies, 7 (46.7%) assessed single interventions and the
223 remaining 8 (53.3%) tested bundled interventions; intervention duration ranged from 6 weeks to 3 years.
224 Audit or review and feedback of provider prescribing or AMU practices ($n=7$ studies, 46.7%) and
225 education ($n=6$, 40%) were the most common intervention types implemented. Four studies assessed the
226 impact of introducing various online or application-based diagnostic and clinical support tools, three
227 studies introduced prescribing restrictions or pre-authorization requirements, two studies involved the
228 development and/or introduction of a clinical treatment guideline, and one study implemented a
229 diagnostic stewardship strategy to withhold laboratory results if there were no white blood cells or
230 bacteria identified on microscopy.

231 **Fig 2. Effect of interventions on antimicrobial use (proportion of patients receiving antimicrobials).**

232 *Indicates significance <0.05 . **Indicates significance <0.001 . Antimicrobial abbreviations: AMK-
233 amikacin, AMX- amoxicillin, AMC- amoxicillin-clavulanic acid, AMP- ampicillin, CARB- carbapenems,
234 CTX- cefotaxime, CIP- ciprofloxacin, FOF- Fosfomycin, IPM- imipenem, LVX- levofloxacin, MDR-

235 multi-drug resistant, MEM- meropenem, MET- methicillin, NIT- nitrofurantoin, TZP- piperacillin-
236 tazobactam, SXT- trimethoprim-sulfamethoxazole, 3G-CEPH- third-generation cephalosporins. Other
237 abbreviations: HCAP- healthcare associated pneumonia, IV- intravenous, CAP- community-acquired
238 pneumonia, ICU- intensive care unit, IAI- intraabdominal infection, UTI- urinary tract infection, SSTI-
239 skin or soft tissue infection.

240 Six of 42 of the studies (14.3%) that reported on the proportion of patients who received an
241 antimicrobial documented a statistically significant (p value <0.05) increase in AMU after the
242 intervention; the percentage increase averaged 10.01% (SD: 14.5) and ranged from 1.1 to 58.4%. All six
243 of these studies described interventions in high-income countries (Denmark, Japan, Australia, USA,
244 Spain, and Ireland); clinical settings of interventions included secondary or tertiary hospitals ($n=3$
245 studies), academic or university hospitals ($n=2$), and a children's hospital. The majority of these 6 studies
246 implemented bundled interventions ($n=5$, 83.3%); 4 included an audit or review and feedback activity; 3
247 involved the development and/or implementation of a clinical treatment guideline, protocol, or policy; 2
248 involved AMS education or training; 1 study introduced an AMS application; and another study
249 introduced a rapid blood culture diagnostic test. Intervention duration ranged from 2 months to 45
250 months.

251 Seven studies (16.7%) reported simultaneous increases and decreases in different antimicrobial
252 agents and classes that were statistically significant, ranging from a 21.3% pre- to post-intervention
253 increase to a 56% decrease. For example, Leis *et al.*, reported a significant reduction in the proportion of
254 patients prescribed fluoroquinolone (15.3 to 7%, $p<0.001$) and carbapenems (13 to 6.3%, $p<0.001$) and an
255 increase in the proportion of patients prescribed penicillin (10.9 to 32.2%, $p<0.001$) after an intervention
256 that implemented a point-of-care β -lactam allergy skin test among other AMS activities (39). Another
257 intervention described by Yogo *et al.* aimed to reduce broad-spectrum antibiotic prescribing rates and
258 treatment durations at time of hospital discharge by introducing institutional guidance for oral step-down
259 antibiotic selection and duration of therapy and implemented a pharmacy audit and real-time

260 recommendations of discharge prescriptions (40). This study documented a significant pre- to post-
261 intervention decrease in fluoroquinolone use (38.1 to 25%, $p=0.001$) and a significant increase in the
262 proportion of patients prescribed azithromycin (12 to 20%, $p=0.01$). Across all datapoints reported in
263 these 7 studies, there was an average 1.8% decrease in the proportion of patients receiving antimicrobials.

264 **Theme 2: Appropriateness of therapy and adherence to treatment guidelines,** 265 **protocols, and policies**

266 We extracted data from 38 studies that described pre- to post-intervention changes in the
267 adherence/concordance of AMU or prescribing practices with local, national, or international treatment
268 guidelines or protocols (Fig 3). Of those, 28 studies (73.7%) reported a significant improvement in
269 appropriateness and/or adherence while 1 study (2.6%) reported a significant decline. Most studies that
270 reported improvements in appropriateness of therapy or adherence to guidelines were conducted in high-
271 income countries ($n=20$, 71.4%, Australia; Canada, $n=2$; Denmark; Germany; Greece; Ireland; Israel;
272 Italy, $n=3$); Netherlands; USA, $n=8$) with 2 studies in upper-middle-income (Malaysia, South Africa), 5 in
273 lower-middle (Egypt; India, $n=2$; Kenya; Pakistan), and 1 in low-income countries (Nepal). Most studies
274 assessed bundled interventions ($n=19$, 67.9%) in secondary, tertiary, or academic/teaching hospital
275 settings. Audit or review and feedback; the development of implementation of clinical treatment
276 guidelines, protocols, or policies; and education or training were the most common interventions
277 implemented as the sole intervention or in combination with other intervention activities in 18 (64.3%),
278 16 (57.4%), and 14 (50%) studies, respectively. Intervention duration ranged from 3 months to 6 years.
279 The average increase in the proportion of cases or patients treated with appropriate or guideline-
280 concordant antimicrobial therapies across all studies and indicators where a statistically significant change
281 was reported was 20.8% (SD: 12.3). The study that reported a decline in guideline concordance was
282 conducted in a secondary care hospital in the United Arab Emirates; this study assessed the impact of a 3-
283 month intervention to develop and implement a new treatment guideline and conduct educational lectures
284 for physicians for adopting the guidelines into their practice. The proportion of patients who received

285 antimicrobial treatment that complied with guidelines regarding the timing of discontinuation fell from
286 29.7 to 8.3% (Odds ratio: 0.2, 95% CI: 0.1- 0.4; Chi square $p < 0.001$).

287 **Fig 3. Effect of interventions on appropriateness of antimicrobial therapy or adherence to clinical**
288 **guidelines (including drug selection, dosage, duration, and timing of administration).** *Indicates
289 significance < 0.05 . **Indicates significance < 0.001 .

290 **Theme 3: Antimicrobial stewardship**

291 We extracted AMS data from 20 studies; 9 (45%) of which demonstrated significant
292 improvements in AMS practices and 1 (5%) that reported a significant reduction in AMS practices (Fig
293 4). Two of three studies (66.7%) that assessed changes in intravenous to oral stepdown reported pre- to
294 post-intervention improvements in conversion rates while 7 of 18 studies (38.8%) that assessed changes
295 in the proportion of patients or cases where a culture or clinical diagnostic test was obtained reported
296 significant pre- to post- increases. Of the studies the reported significant improvements in AMS, 3 were
297 conducted in lower-middle-income countries (Egypt, India, Vietnam), 2 in upper-middle-income
298 countries (China, South Africa), and 4 in high-income countries (Canada; USA, $n=4$). Most studies
299 assessed bundled interventions ($n=6$, 66.7%) that were implemented in tertiary or academic health
300 facilities ($n=6$, 66.7%). Four interventions involved the development and/or dissemination of treatment
301 guidelines, protocols, or policies; 4 involved education or training sessions; 4 included the introduction of
302 or changes to antibiotic order forms or clinical-support tools; 3 interventions involved audit or review and
303 feedback; 1 study included the development of a facility antibiogram. Intervention durations ranged from
304 2 months to 24 months. One study assessed the impact of a one-year audit/review and feedback
305 intervention on prescribers at a pediatric hospital in Iran obtaining blood cultures to aid in diagnosis and
306 found that the proportion of patients whose care included a blood culture for diagnosis declined from
307 23.9% pre-intervention to 4.4% post-intervention (OR: 0.1, 95% CI: 0.04-0.5; Chi square $p < 0.001$). The
308 study also reported non-significant pre- to post-intervention declines in the proportion of patients whose
309 diagnosis was aided by tracheal and urine cultures.

310 **Fig 4. Effect of interventions on the utilization of clinical diagnostic and laboratory tests/cultures**
311 **and intravenous to oral conversion rates.** *Indicates significance <0.05. **Indicates significance
312 <0.001. Abbreviations: AST- antimicrobial susceptibility testing, IV- intravenous, PO- per os (by
313 mouth/oral).

314 **Theme 4: Antimicrobial resistance**

315 Of the studies that met our inclusion criteria and reported on our primary outcomes of interest, 11
316 reported on our secondary outcome of pre- to post-intervention changes in AMR (Fig 5). Across these
317 studies, data was reported for 60 unique organism-antimicrobial combinations. Five studies (45.5%)
318 reported significant decreases in the proportion of isolates that were resistant to antibiotics or the
319 proportion of patients with drug-resistant infections across 17 antimicrobial-organism combinations while
320 3 studies (27.3%) reported both significant increases and decreases in resistance rates for different
321 antimicrobial-organism combinations. All 8 studies reporting AMR data were conducted in high-income
322 countries (Canada, Israel, France, Japan, Korea, Spain, and the USA; n=2). The 5 studies that reported
323 only decreases in resistance rates were conducted in either acute care hospitals, nursing homes, public
324 hospitals, or teaching hospitals (n=2); most of the studies tested single activity interventions (n=4, 80%)
325 including introducing a treatment management protocol, and audit or review and feedback (n=3). The
326 bundled intervention consisted of the implementation of an AMS toolkit and subsequent education and an
327 antibiotic mobile team for daily AMS coordination.

328 **Fig 5. Effect of interventions on the proportion of isolates/infections resistant to various**
329 **antimicrobials.** *Indicates significance <0.05. **Indicates significance <0.001. Antimicrobial
330 Abbreviations: AMK- amikacin, AMX- amoxicillin, AMC- amoxicillin-clavulanic acid, AMP-
331 ampicillin, CARB- carbapenems, CTX- cefotaxime, CIP- ciprofloxacin, FOF- Fosfomycin, IPM-
332 imipenem, LVX- levofloxacin, MDR- multi-drug resistant, MEM- meropenem, MET- methicillin, NIT-
333 nitrofurantoin, TZP- piperacillin-tazobactam, SXT- trimethoprim-sulfamethoxazole, 3G-CEPH- third-
334 generation cephalosporins.

335 The 3 studies that reported a combination of significant pre- to post-intervention changes were
336 conducted in nursing homes or tertiary/teaching hospitals (n=2); two of these interventions consisted of
337 bundled AMS activities. One intervention described by Ziv-On *et al.* consisted of review and feedback,
338 education, and restricted use of certain antibiotics that required pre-prescription authorization (41). There
339 were significant pre- to post-intervention decreases in the proportion of cultured isolates resistant to
340 gentamycin (19% to 15.4%, OR: 0.8, 95% CI: 0.677-0.888, Chi-square $p<0.001$) and ciprofloxacin
341 (33.8% to 29.9%, OR: 0.8, 95% CI: 0.7-0.9, Chi-square $p=0.001$) and significant increases in the
342 proportion of isolates resistant to cefuroxime (26.5 to 33.8%, OR: 1.4, Chi-square $p<0.001$) and
343 amoxicillin-clavulanic acid (29.7 to 32.6%, OR: 1.1, 95% CI: 1.03-1.3, Chi-square $p=0.007$). There were
344 decreases in average quarterly use of aminoglycoside (gentamycin) from 2.3 (SD: 0.2) to 1.7 (SD: 0.3)
345 daily defined doses/100 days of admission, quinolones (ciprofloxacin) 10.9 (SD: 0.7) to 6.71 (SD: 1.8),
346 second-generation cephalosporins (cefuroxime) from 11.3 (SD: 0.7) to 8.6 (SD: 2.7), and amoxicillin-
347 clavulanic acid from 19.8 (SD: 4.7) to 9.9 (SD: 3.7).

348 The second bundled study by Tandan *et al.* consisted of the introduction of a treatment guideline,
349 education, and audit and feedback (42). There were significant decreases in the proportion of cultured *E.*
350 *coli* isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7, Chi-square $p<0.001$) and
351 trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square $p<0.001$) and
352 *Klebsiella pneumoniae* and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334-
353 0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion
354 of *Proteus* spp. isolates that were multi-drug resistant (6.7 to 14.8%, OR: 2.3, 95% CI: 1.1-4.6, Chi-
355 square $p=0.02$). The study did not report data on changes in AMU.

356 The third intervention described by Kim *et al.* tested the impact of restricting prescription of
357 third-generation cephalosporin through a computerized antimicrobial prescription program (43). There
358 were significant decreases in the proportion of *P. aeruginosa* isolates resistant to imipenem (22.8% to
359 16.7%, OR: 0.6, 95% CI: 0.5-0.9) and *A. baumannii* isolates resistant to imipenem (13.7% to 6.6%, OR:
360 0.4, 95% CI: 0.3-0.7) and trimethoprim-sulfamethoxazole (53.8% to 45.8%, OR: 0.7, 95% CI: 0.6-0.9)

361 but a significant increase in the proportion of extended-spectrum beta-lactamase (ESBL)-producing *K.*
362 *pneumoniae* isolates (8.1% to 20.6%, OR: 2.9, 95% CI: 2.0-4.3). There was no significant change in
363 carbapenem (imipenem) or beta-lactamase inhibitor use, and data on sulfonamide (trimethoprim-
364 sulfamethoxazole) use was not reported.

365 **Theme 5: Clinical Outcomes**

366 We extracted clinical outcome data from 57 of 301 total studies (Fig 6). Of three studies that
367 reported the proportion of patients who were admitted to the intensive care unit before and after the
368 intervention, only one reported a statistically significant change, a decrease from 44.5% to 35.5% of
369 patients (OR: 0.7, 95% CI: 0.5-1.0) (44). Three separate studies reported the proportion of patients who
370 experienced an adverse event before and after the intervention, and one reported a statistically significant
371 change, an increase from 1.1% to 10.0% (OR: 9.9, 95% CI: 8.4-11.6) (45). Of 41 total studies that
372 reported data on patient mortality before and after AMS interventions, 6 (14.6%) reported statistically
373 significant decreases in the proportion of patients who died while 2 (4.8%) reported statistically
374 significant increases in the proportion of patients who died; all other studies reported no significant
375 change in mortality rates. Of 18 studies that reported on readmission rates, one study reported a
376 significant increase and one a significant decrease in readmission after the intervention compared to
377 before. Six of 8 studies (75%) that recorded the proportion of patients who experienced a recurrence or re-
378 infection reported no significant pre- to post-intervention while two (25%) reported significant decreases.
379 Finally, three studies reported on the proportion of patients experiencing treatment failure before and after
380 interventions with only one reporting a significant pre- to post-intervention change, a decrease from
381 33.3% to 14.0% (OR: 0.3, 95% CI: 0.2-0.5) (46).

382 **Fig 6. Effect of interventions on clinical outcomes (ICU admission rate, adverse events, mortality,**
383 **readmission or return visit to a health facility, recurrence of infection, and treatment failure).**

384 *Indicates significance <0.05. **Indicates significance <0.001. Abbreviations: ICU- intensive care unit.

385 Based on univariable t-tests and multivariable linear regression, there were no statistically
386 significant ($p < 0.05$) associations between pre- to post-intervention absolute differences and intervention
387 type, duration, or setting of intervention across any of our study outcomes in Themes 1-5.

388 **Discussion**

389 Overall, there was a paucity of studies that assessed the impact of behavior-change interventions
390 on AMU, AMS, and AMR in the animal health sector; further evidence is needed to understand best
391 practices in these settings. A minority of studies conducted in the human health sector (35.7%) reported
392 significant ($p < 0.05$) pre- to post-intervention decreases in AMU while a majority (73.7%) reported
393 significant improvements in adherence of antimicrobial therapies to local, national, or international
394 guidelines. Of 20 studies, 45% demonstrated significant improvements in AMS practices while only 1
395 study reported a significant reduction in AMS practices. Eleven studies reported on pre- to post-
396 intervention changes in the AMR burden, all of which took place in high-income countries. Five of those
397 studies (45.5%) reported significant decreases in the proportion of isolates that were resistant to
398 antibiotics or the proportion of patients with drug-resistant infections across 17 antimicrobial-organism
399 combinations; 3 studies (27.3%) reported both significant increases and decreases in resistance rates for
400 different antimicrobial-organism combinations. Generally, significant pre- to post-intervention changes in
401 clinical outcomes – including ICU admission, mortality, adverse events, reinfection, mortality, and
402 treatment failure rates – were infrequent with studies more commonly reporting improvements across
403 those outcomes. Our study found no intervention characteristics that were associated with overall success
404 the various thematic areas in any setting or subsetting included.

405 This study had several limitations. We limited our review to peer-reviewed studies which may
406 have overlooked a significant number of ongoing interventions in various settings to improve AMR,
407 AMU, and AMS and may have also introduced a publication bias where successful studies are more
408 likely to be more published than unsuccessful interventions. Moreover, we only considered interventions
409 that targeted behavior change among stakeholder groups involved in the use or prescription of

410 antimicrobials thereby overlooking other important interventions such as those that aim to increase
411 awareness and knowledge of AMR, AMU, and AMS; those that effect funding levels or policies; those
412 that change access to clinically appropriate antimicrobials or other critical diagnostic and laboratory
413 testing infrastructure; among other interventions and efforts that can effectively improve AMU and AMS
414 and reduce AMR amongst human and animal populations. There were also limitations in the studies
415 included in our final analysis. First, the majority of studies took place in developed countries; given the
416 disparities in healthcare infrastructure, human resources, and AMR burden in high- versus low-resource
417 settings, our findings may not be globally applicable. Notably, adherence to guidelines was the most
418 improved intervention outcome in the human health sector; however, in many LMICs, local or national
419 clinical treatment guidelines are often unavailable or outdated. A 2021 review of antimicrobial treatment
420 guidelines in Africa found that only 20 of the 55 Africa Union member states had national guidelines at
421 the time of the study, and only 10 member states had updated those guidelines since 2015 (47).

422 There were also limitations in the quality of evidence provided by the included studies. Few
423 interventions utilized random allocation of treatment groups; most interventions were assessed using
424 pre/post observational studies with no control group. The duration of interventions varied widely with
425 many only assessing short-term impacts of interventions. Moreover, few studies described the theories
426 underpinning behavior-change interventions which may improve effectiveness (48). Our quality
427 assessment examined the risk of selection bias, study design, data collection methods, intervention
428 integrity, and analyses, among other criteria. Overall, 4 of 11 studies (36.4%) that described interventions
429 in the animal health or agriculture sectors and 129 of the 290 studies (44.5%) that described interventions
430 in the human health sector were determined to have strong overall quality; therefore, there is room for
431 improvement in overall study quality.

432 Overall, there is a need to increase the evidence base of behavior-change interventions regarding
433 AMU, AMS, and AMR in the animal health and LMIC settings. Due to heterogeneity in the study settings
434 and designs, it is difficult to identify which practices are most impactful across the board. There is a need
435 to systematize approaches to assessing the impact of interventions and for studies to collect and report

436 data representing the multiple ways AMR and AMS impacts clinical practice and outcomes; for example,
437 studies should consider not only overall AMU rates but the clinical appropriateness of therapy; adherence
438 to local, national, or international guidelines; clinical outcomes, AMS practices, cost and duration of
439 patient stays; and clinical outcomes. There is a need to systematically assess interventions to allow for a
440 thorough comparative analysis so that best practices in various settings can be identified for scaling these
441 efforts.

442 **Acknowledgements**

443 We thank Nathan Freeman for assistance with the quality assessment.

444

445 **References**

- 446 1. World Health Organization. Antimicrobial resistance [Internet]. Geneva; 2021 Nov [cited 2022
447 Sep 19]. Available from: [https://www.who.int/news-room/fact-sheets/detail/antimicrobial-](https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance)
448 resistance
- 449 2. World Bank Group. Drug-Resistant Infections- A Threat to Our Economic Future. Drug-Resistant
450 Infections. Washington, DC; 2017.
- 451 3. George A. Antimicrobial resistance, trade, food safety and security. One Heal [Internet]. 2018 Jun
452 1 [cited 2022 Oct 1];5:6. Available from: [/pmc/articles/PMC5725214/](https://pubmed.ncbi.nlm.nih.gov/35725214/)
- 453 4. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden
454 of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet [Internet]. 2022 Feb 12
455 [cited 2022 Sep 6];399(10325):629–55. Available from:
456 <http://www.thelancet.com/article/S0140673621027240/fulltext>
- 457 5. Nelson RE, Hatfield KM, Wolford H, Samore MH, Scott RD, Reddy SC, et al. National Estimates
458 of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among
459 Hospitalized Patients in the United States. Clin Infect Dis [Internet]. 2021 Jan 29 [cited 2022 Sep
460 6];72(Supplement_1):S17–26. Available from:
461 https://academic.oup.com/cid/article/72/Supplement_1/S17/6123350
- 462 6. Magnusson U, Moodley A, Osbjør K. Antimicrobial resistance at the livestock-human interface:
463 implications for Veterinary Services. Rev Sci Tech Off Int Epiz. 2021;40(2).
- 464 7. Cooper B, Okello WO. An economic lens to understanding antimicrobial resistance: disruptive
465 cases to livestock and wastewater management in Australia. Aust J Agric Resour Econ [Internet].
466 2021 Oct 1 [cited 2022 Oct 1];65(4):900–17. Available from:
467 <https://onlinelibrary.wiley.com/doi/full/10.1111/1467-8489.12450>

- 468 8. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and
469 geographic convergence in antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci U*
470 *S A* [Internet]. 2018 Apr 10 [cited 2022 Sep 19];115(15):E3463–70. Available from:
471 <https://www.pnas.org/doi/abs/10.1073/pnas.1717295115>
- 472 9. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, et al. Assessment
473 of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of
474 pharmaceutical sales data. *Lancet Infect Dis* [Internet]. 2021 Jan 1 [cited 2022 Oct 1];21(1):107–
475 15. Available from: <http://www.thelancet.com/article/S1473309920303327/fulltext>
- 476 10. J G, M B, B W. Antibiotic prescribing practice and adherence to guidelines in primary care in the
477 Cape Town Metro District, South Africa. *S Afr Med J* [Internet]. 2018 Mar 28 [cited 2022 Oct
478 1];108(4):304. Available from: <https://pubmed.ncbi.nlm.nih.gov/29629681/>
- 479 11. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health
480 care settings in China. *JAMA Intern Med* [Internet]. 2014 Dec 1 [cited 2022 Oct 1];174(12):1914–
481 20. Available from: <https://pubmed.ncbi.nlm.nih.gov/25285394/>
- 482 12. Sarwar MR, Saqib A, Ifikhar S, Sadiq T. Antimicrobial use by WHO methodology at primary
483 health care centers: A cross sectional study in Punjab, Pakistan 11 Medical and Health Sciences
484 1117 Public Health and Health Services. *BMC Infect Dis* [Internet]. 2018 Sep 29 [cited 2022 Oct
485 1];18(1):1–9. Available from: [https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3407-z)
486 [018-3407-z](https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-018-3407-z)
- 487 13. Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H, Calle GM, et al. The worldwide
488 antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey:
489 Developing hospital-quality indicators of antibiotic prescribing for children. *J Antimicrob*
490 *Chemother*. 2016;71(4):1106–17.
- 491 14. Tiseo K, Huber L, Gilbert M, Robinson TP, Van Boeckel TP. Global Trends in Antimicrobial Use

- 492 in Food Animals from 2017 to 2030. *Antibiotics* [Internet]. 2020 Dec 1 [cited 2022 Sep
493 19];9(12):1–14. Available from: [/pmc/articles/PMC7766021/](https://pubmed.ncbi.nlm.nih.gov/37766021/)
- 494 15. Schar D, Klein EY, Laxminarayan R, Gilbert M, Van Boeckel TP. Global trends in antimicrobial
495 use in aquaculture. *Sci Reports* 2020 101 [Internet]. 2020 Dec 14 [cited 2022 Oct 1];10(1):1–9.
496 Available from: <https://www.nature.com/articles/s41598-020-78849-3>
- 497 16. Frost I, Craig J, Joshi J, Faure K, Laxminarayan R. *Access Barriers to Antibiotics*. Washington,
498 DC; 2019.
- 499 17. Owens RC. Antimicrobial stewardship: concepts and strategies in the 21st century. *Diagn
500 Microbiol Infect Dis* [Internet]. 2008 May [cited 2022 Oct 1];61(1):110–28. Available from:
501 <https://pubmed.ncbi.nlm.nih.gov/18384997/>
- 502 18. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. *Clin
503 Microbiol Rev* [Internet]. 2005 Oct [cited 2022 Oct 1];18(4):638–56. Available from:
504 <https://pubmed.ncbi.nlm.nih.gov/16223951/>
- 505 19. Garau J, Bassetti M. Role of pharmacists in antimicrobial stewardship programmes. *Int J Clin
506 Pharm* [Internet]. 2018 Oct 1 [cited 2022 Oct 1];40(5):948–52. Available from:
507 <https://pubmed.ncbi.nlm.nih.gov/30242589/>
- 508 20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and
509 meta-analyses: the PRISMA statement. *BMJ* [Internet]. 2009 Jul 21 [cited 2022 Oct
510 10];339(7716):332–6. Available from: <https://www.bmj.com/content/339/bmj.b2535>
- 511 21. National Library of Medicine. *Pubmed.gov* [Internet]. 1996. Available from:
512 <https://pubmed.ncbi.nlm.nih.gov/>
- 513 22. Clarivate. *Web of Science*. 1997; Available from:
514 <https://access.clarivate.com/login?app=wos&alternative=true&shibShireURL=https:%2F%2Fww>

- 515 [w.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https:%2F%2Fwww.web](https://www.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https:%2F%2Fwww.web)
516 [ofknowledge.com%2F&roaming=true](https://www.webofknowledge.com%2F&roaming=true)
- 517 23. Elsevier. Embase. 1947; Available from: <https://www.embase.com/>
- 518 24. Centre for Agriculture and Bioscience International. 1910; Available from: <https://www.cabi.org/>
- 519 25. Cochrane Library. Cochrane Database of Systematic Reviews. Available from:
520 <https://www.cochranelibrary.com/cdsr/about-cdsr>
- 521 26. The World Bank. World Bank Country and Lending Groups [Internet]. 2022 [cited 2022 Oct 1].
522 Available from: [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
523 [country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 524 27. Effective Public Health Practice Project. Quality Assessment Tool for Quantitative Studies. 1998;
- 525 28. Phu DH, Cuong N Van, Truong DB, Kiet BT, Hien VB, Thu HTV, et al. Reducing Antimicrobial
526 Usage in Small-Scale Chicken Farms in Vietnam: A 3-Year Intervention Study. *Front Vet Sci*.
527 2021 Jan 28;7:1244.
- 528 29. Hubbuch A, Peter R, Willi B, Hartnack S, Müntener C, Naegeli H, et al. Comparison of
529 antimicrobial prescription patterns in calves in Switzerland before and after the launch of online
530 guidelines for prudent antimicrobial use. *BMC Vet Res* [Internet]. 2021 Dec 1 [cited 2022 Oct
531 1];17(1):1–14. Available from: [https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-](https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-02704-w)
532 [02704-w](https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-02704-w)
- 533 30. Gerber M, Dürr S, Bodmer M. Reducing Antimicrobial Use by Implementing Evidence-Based,
534 Management-Related Prevention Strategies in Dairy Cows in Switzerland. *Front Vet Sci*
535 [Internet]. 2021 Jan 18 [cited 2022 Oct 1];7. Available from:
536 <https://pubmed.ncbi.nlm.nih.gov/33537355/>
- 537 31. Verliat F, Hemonic A, Chouet S, Le Coz P, Liber M, Jouy E, et al. An efficient cephalosporin

- 538 stewardship programme in French swine production. *Vet Med Sci* [Internet]. 2021 Mar 1 [cited
539 2022 Oct 1];7(2):432–9. Available from:
540 <https://onlinelibrary.wiley.com/doi/full/10.1002/vms3.377>
- 541 32. Collineau L, Rojo-Gimeno C, Léger A, Backhans A, Loesken S, Nielsen EO, et al. Herd-specific
542 interventions to reduce antimicrobial usage in pig production without jeopardising technical and
543 economic performance. *Prev Vet Med*. 2017 Sep 1;144:167–78.
- 544 33. Speksnijder DC, Graveland H, Eijck IAJM, Schepers RWM, Heederik DJJ, Verheij TJM, et al.
545 Effect of structural animal health planning on antimicrobial use and animal health variables in
546 conventional dairy farming in the Netherlands. *J Dairy Sci* [Internet]. 2017 Jun 1 [cited 2022 Oct
547 1];100(6):4903–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/28390724/>
- 548 34. Jensen VF, de Knecht L V., Andersen VD, Wingstrand A. Temporal relationship between decrease
549 in antimicrobial prescription for Danish pigs and the “Yellow Card” legal intervention directed at
550 reduction of antimicrobial use. *Prev Vet Med* [Internet]. 2014 Dec 1 [cited 2022 Oct 1];117(3–
551 4):554–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/25263135/>
- 552 35. Singleton DA, Rayner A, Brant B, Smyth S, Noble PJM, Radford AD, et al. A randomised
553 controlled trial to reduce highest priority critically important antimicrobial prescription in
554 companion animals. *Nat Commun* 2021 121 [Internet]. 2021 Mar 11 [cited 2022 Oct 1];12(1):1–
555 14. Available from: <https://www.nature.com/articles/s41467-021-21864-3>
- 556 36. Lehner C, Hubbuch A, Schmitt K, Schuepbach-Regula G, Willi B, Mevissen M, et al. Effect of
557 antimicrobial stewardship on antimicrobial prescriptions for selected diseases of dogs in
558 Switzerland. *J Vet Intern Med* [Internet]. 2020 Nov 1 [cited 2022 Oct 1];34(6):2418–31. Available
559 from: <https://pubmed.ncbi.nlm.nih.gov/33112451/>
- 560 37. Hubbuch A, Schmitt K, Lehner C, Hartnack S, Schuller S, Schüpbach-Regula G, et al.
561 Antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online

- 562 antimicrobial stewardship tool. BMC Vet Res [Internet]. 2020 Jul 3 [cited 2022 Oct 1];16(1):1–13.
563 Available from: <https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-02447-8>
- 564 38. Hopman NEM, Portengen L, Hulscher MEJL, Heederik DJJ, Verheij TJM, Wagenaar JA, et al.
565 Implementation and evaluation of an antimicrobial stewardship programme in companion animal
566 clinics: A stepped-wedge design intervention study. PLoS One [Internet]. 2019 Nov 1 [cited 2022
567 Oct 1];14(11). Available from: <https://pubmed.ncbi.nlm.nih.gov/31738811/>
- 568 39. Leis JA, Palmay L, Ho G, Raybardhan S, Gill S, Kan T, et al. Point-of-Care β -Lactam Allergy
569 Skin Testing by Antimicrobial Stewardship Programs: A Pragmatic Multicenter Prospective
570 Evaluation. Clin Infect Dis [Internet]. 2017 Oct 1 [cited 2022 Nov 27];65(7):1059–65. Available
571 from: <https://pubmed.ncbi.nlm.nih.gov/28575226/>
- 572 40. Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, et al. Intervention to
573 Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital
574 Discharge: A Novel Stewardship Approach. Infect Control Hosp Epidemiol [Internet]. 2017 May
575 1 [cited 2022 Nov 27];38(5):534–41. Available from: <https://pubmed.ncbi.nlm.nih.gov/28260538/>
- 576 41. Ziv-On E, Friger MD, Saidel-Odes L, Borer A, Shimoni O, Nikonov A, et al. Impact of an
577 Antibiotic Stewardship Program on the Incidence of Resistant Escherichia coli: A Quasi-
578 Experimental Study. Antibiot (Basel, Switzerland) [Internet]. 2021 Feb 1 [cited 2022 Nov
579 27];10(2):1–10. Available from: <https://pubmed.ncbi.nlm.nih.gov/33578840/>
- 580 42. Tandan M, Sloane PD, Ward K, Weber DJ, Vellinga A, Kistler CE, et al. Antimicrobial resistance
581 patterns of urine culture specimens from 27 nursing homes: Impact of a two-year antimicrobial
582 stewardship intervention. Infect Control Hosp Epidemiol [Internet]. 2019 Jul 1 [cited 2022 Nov
583 27];40(7):780–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/31057141/>
- 584 43. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum β -
585 lactamase-producing *Klebsiella pneumoniae* using a computer-assisted management program to

- 586 restrict third-generation cephalosporin use. *J Antimicrob Chemother* [Internet]. 2008 Aug [cited
587 2022 Nov 27];62(2):416–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/18413317/>
- 588 44. Shemanski S, Bennett N, Essmyer C, Kennedy K, Buchanan DM, Warnes A, et al. Centralized
589 Communication of Blood Culture Results Leveraging Antimicrobial Stewardship and Rapid
590 Diagnostics. *Open Forum Infect Dis* [Internet]. 2019 Sep 1 [cited 2022 Nov 27];6(9). Available
591 from: <https://academic.oup.com/ofid/article/6/9/ofz321/5532664>
- 592 45. Shawki MA, AlSetohy WM, Ali KA, Ibrahim MR, El-Husseiny N, Sabry NA. Antimicrobial
593 stewardship solutions with a smart innovative tool. *J Am Pharm Assoc (2003)* [Internet]. 2021 Sep
594 1 [cited 2022 Nov 27];61(5):581-588.e1. Available from:
595 <https://pubmed.ncbi.nlm.nih.gov/33962893/>
- 596 46. Niwa T, Yonetamari J, Hayama N, Fujibayashi A, Ito-Takeichi S, Suzuki K, et al. Clinical impact
597 of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with
598 antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese
599 tertiary hospital. *Int J Clin Pract* [Internet]. 2019 May 1 [cited 2022 Nov 27];73(5). Available
600 from: <https://pubmed.ncbi.nlm.nih.gov/30810264/>
- 601 47. Craig J, Hiban K, Frost I, Kapoor G, Alimi Y, Varma JK. Comparison of national antimicrobial
602 treatment guidelines, African Union. *Bull World Health Organ* [Internet]. 2022 Jan 1 [cited 2022
603 Apr 7];100(1):50. Available from: [/pmc/articles/PMC8722630/](https://pubmed.ncbi.nlm.nih.gov/398722630/)
- 604 48. Korda H, Itani Z. Harnessing social media for health promotion and behavior change. *Health
605 Promot Pract* [Internet]. 2013 Jan [cited 2022 Nov 29];14(1):15–23. Available from:
606 <https://pubmed.ncbi.nlm.nih.gov/21558472/>

154,106 total entries returned

4,893 duplicates excluded

148,639 excluded due to
irrelevance following title
and abstract review


36 identified as review
articles

538 studies (517 in the human
health sector, 14 animal health)
underwent full-text review

283 excluded due to
irrelevance or data
missingness


46 additional articles
identified through review of
review articles

301 entries (290 human health, 11
animal health) underwent data
extraction




% patients receiving antimicrobial

| ID | Antimicrobial (dose, time of administration, condition) | % patients receiving antimicrobial | | OR |
|-------|---|------------------------------------|------|------|
| | | Pre | Post | |
| 507** | Any | 62.6 | 7.2 | 0.10 |
| 617* | Any (ICU) | 3.1 | 0 | 0.1 |
| 30** | Any | 79 | 28.2 | 0.1 |
| 600 | Any | 3.9 | 0 | 0.1 |
| 547** | Any | 98 | 94 | 0.2 |
| 604 | Any | 3 | 1 | 0.3 |
| 9** | Any | 5.6 | 2 | 0.3 |
| 388** | Any (urgent care) | 8.5 | 2.3 | 0.3 |
| 415** | Any | 38.2 | 18.2 | 0.4 |
| 368** | Any (prophylaxis) | 91.3 | 80.3 | 0.4 |
| 605** | Any | 13 | 6 | 0.4 |
| 553** | Any (UTI) | 11.1 | 4.9 | 0.4 |
| 407** | Any | 70.3 | 49.6 | 0.4 |
| 553** | Any (UTI) | 14.5 | 7.8 | 0.5 |
| 553 | Any (at discharge) | 1.6 | 0 | 0.5 |
| 494 | Any (UTI) | 85 | 77.6 | 0.6 |
| 488** | Any (URTI) | 33.5 | 23.3 | 0.6 |
| 129* | Any (pneumonia) | 37.2 | 26 | 0.6 |
| 303* | Any | 30 | 20.5 | 0.6 |
| 129 | Any (ICU) | 42.7 | 31.5 | 0.6 |
| 586** | Any | 59.9 | 50.2 | 0.7 |
| 253 | Any | 39 | 30.2 | 0.7 |
| 415** | Any (inpatient) | 48.7 | 43.4 | 0.8 |
| 398 | Any | 59.5 | 54.4 | 0.8 |
| 129 | Any (at discharge) | 47.7 | 45 | 0.9 |
| 129 | Any (SSTI) | 11.6 | 10 | 0.9 |
| 253 | Any (at discharge) | 59.4 | 61.3 | 1.1 |
| 129 | Any | 13.6 | 14.5 | 1.1 |
| 139 | Any (UTI) | 17.1 | 21.5 | 1.3 |
| 368 | Any | 3 | 4.7 | 1.6 |
| 129* | Any (IAI) | 16.1 | 24.5 | 1.7 |
| 93** | Any | 22.2 | 34.5 | 1.8 |
| 10 | Any | 8 | 14 | 1.9 |
| 617 | Any | 2.3 | 5 | 2.2 |
| 146* | Any | 64.4 | 82.7 | 2.6 |
| 272* | Any | 0.6 | 1.6 | 2.9 |
| 372 | Any (acute tonsilitis) | 33.9 | 64.4 | 3.5 |
| 451** | Any | 76 | 92.6 | 3.9 |
| 446 | Any | 89.4 | 97.7 | 5.8 |
| 617** | Any (ICU) | 20.5 | 78.9 | 14.5 |
| 159** | Any | 37.6 | 19.7 | 0.4 |
| 318 | Any | 62 | 15.6 | 0.5 |
| 129* | Any (>1) | 45.2 | 32.5 | 0.6 |
| 337 | Any (>1) | 62.3 | 56.6 | 0.8 |
| 606 | Any (>1) | 12.6 | 14.8 | 1.2 |
| 190 | Any (>1) | 5 | 7 | 1.3 |
| 604 | Any (>2) | 17 | 11 | 0.6 |
| 617** | Any (2) | 74.1 | 16.1 | 0.1 |
| 129 | Any (3) | 8 | 6 | 0.7 |
| 129 | Any (4) | 5 | 5 | 1.00 |
| 93 | Any (IV) | 55.3 | 58.9 | 1.2 |
| 471 | AMB | 33.3 | 21.1 | 0.5 |
| 335 | AMB | 0 | 4.8 | 2.2 |
| 604 | AMB | 0 | 4.8 | 2.2 |
| 303 | AMC (CAP) | 36.7 | 1 | 0.6 |
| 298* | AMC (CAP) | 1 | 1 | 0.6 |
| 605 | AMG | 1 | 30.8 | 0.9 |
| 368 | AMG | 32.8 | 7 | 1.2 |
| 104 | AMK (prophylaxis) | 6 | 5.2 | 0.7 |
| 272 | AMP | 6.8 | 4 | 1.1 |
| 190 | AMP | 3 | 4 | 1.1 |
| 368 | AMX | 1.1 | 0.8 | 0.7 |
| 303 | AMX | 85 | 83 | 0.9 |
| 471* | Antifungals | 42.4 | 62.5 | 2.3 |
| 303 | AZM | 9 | 4 | 0.4 |
| 604* | AZM | 12 | 20 | 1.8 |
| 272* | AZM | 2.2 | 4.4 | 2.00 |
| 605** | CARBA | 13 | 6.3 | 0.4 |
| 70 | CARBA | 26.3 | 20.9 | 0.7 |
| 471 | CAS | 3 | 1.3 | 0.4 |
| 272 | CAZ | 3.2 | 3.8 | 1.2 |
| 368 | CEPH | 42 | 42.9 | 1.00 |
| 605 | CEPH | 40 | 41.4 | 1.1 |
| 190** | CEPH | 6 | 11.4 | 2.00 |
| 190* | 1GCEPH | 1.3 | 3.3 | 2.6 |
| 604 | 2G, 3GCEPH | 1 | 2 | 2.00 |
| 190 | 2GCEPH | 1.8 | 2.6 | 1.4 |
| 190* | 3GCEPH | 2.9 | 5.1 | 1.8 |
| 190 | 4GCEPH | 0 | 4 | 6.4 |
| 272 | CEFZ | 0.3 | 3 | 0.8 |
| 272 | CIP | 2.1 | 3.2 | 1.6 |
| 272 | CLI | 1.1 | 8 | 0.7 |
| 605 | CLI | 1 | 0.6 | 0.7 |
| 104 | CLI | 6 | 7 | 1.2 |
| 604 | CLI | 9 | 12 | 1.4 |
| 253 | CLI (at discharge) | 93.8 | 1.6 | 0.00 |
| 272 | CLOX | 1.2 | 1.1 | 0.9 |
| 604 | CLR | 4 | 1 | 0.2 |
| 140 | CLR | 51.7 | 76 | 3.00 |
| 104* | CRO (surgical) | 16.4 | 5.5 | 0.3 |
| 149 | CRO | 28 | 38 | 1.6 |
| 272* | CRO, CTX | 29.7 | 24.9 | 0.8 |
| 303 | CXM | 1 | 1 | 0.9 |
| 104 | CXM (surgical) | 34 | 46.6 | 1.9 |
| 604 | DOX | 6 | 8 | 1.4 |
| 272 | FEP | 9.5 | 9.7 | 1.00 |
| 471 | FLC | 24.2 | 32.9 | 1.5 |
| 335 | FLC | 19 | 31 | 1.9 |
| 600 | FLU (IV) | 0 | 0 | 0.6 |
| 605** | FLU | 15.3 | 7 | 0.4 |
| 604* | FLU | 38.1 | 25 | 0.5 |
| 600 | FLU (oral) | 49 | 39.5 | 0.7 |
| 253 | FLU (at discharge) | 3.1 | 6.4 | 2.1 |
| 335 | GEN | 5.3 | 5.9 | 1.1 |
| 598** | L VX | 51.2 | 27.2 | 0.4 |
| 598 | L VX | 26.5 | 19.6 | 0.7 |
| 70 | LZD | 5 | 0.8 | 1.7 |
| 419 | MEM | 10.4 | 1.47 | 0.1 |
| 272** | MEM | 6.6 | 10.7 | 1.7 |
| 419** | MEM, VAN | 53.7 | 5.88 | 0.1 |
| 335 | MFG | 26.2 | 64.3 | 0.6 |
| 471 | MFG | 24.2 | 32.9 | 1.5 |
| 602** | MOX (>2 doses) | 82 | 26 | 0.1 |
| 602* | MOX (1 dose) | 18 | 26 | 1.6 |
| 604 | MTZ | 10 | 6 | 0.6 |
| 253 | MTZ | 14.1 | 9.5 | 0.6 |
| 368 | MTZ | 19.6 | 17.8 | 0.9 |
| 272 | MTZ | 8.7 | 9.9 | 1.2 |
| 602** | MXF | 100 | 52 | 0.00 |
| 104 | NIT (surgical) | 2 | 7 | 0.4 |
| 604 | NIT | 3 | 3 | 1.00 |
| 253 | NIT (at discharge) | 6.3 | 11.1 | 1.9 |
| 253 | None (at discharge) | 59.4 | 60.3 | 1.00 |
| 253 | None | 7.8 | 7.9 | 1.00 |
| 190 | PEN | 1 | 2.3 | 2.3 |
| 605** | PEN | 10.9 | 32.2 | 3.9 |
| 604 | PEN, AMOX | 5 | 3 | 0.6 |
| 70* | PMB | 6.2 | 11.1 | 1.9 |
| 335 | POS | 0 | 0 | 1.00 |
| 471 | POS | 0 | 2.6 | 1.8 |
| 451* | QUIN | 20.9 | 7.4 | 0.3 |
| 272 | SAM | 1.9 | 1.2 | 0.6 |
| 190* | SAM | 5 | 1.6 | 3.2 |
| 253 | SXT (at discharge) | 14.1 | 4.8 | 0.3 |
| 604 | SXT | 7 | 6 | 0.8 |
| 70 | TGC | 0 | 0 | 0.4 |
| 272* | TZP | 2.3 | 8 | 0.3 |
| 368 | TZP | 1.5 | 3 | 2.00 |
| 298 | TZP (HCAP) | 40.8 | 58.7 | 2.1 |
| 149* | TZP | 4 | 9 | 2.4 |
| 190* | TZP | 6 | 1.9 | 3.00 |
| 419** | VAN | 35.8 | 4.4 | 0.1 |
| 523 | VAN (catheter infection) | 2.6 | 1.2 | 0.5 |
| 523 | VAN (SSTI) | 14.3 | 9.8 | 0.6 |
| 523 | VAN (fever) | 22.1 | 15.8 | 0.7 |
| 523 | VAN (fever, neutropenia) | 33.8 | 29.3 | 0.8 |
| 272 | VAN | 18.6 | 16.7 | 0.9 |
| 605 | VAN | 6.1 | 6 | 1.00 |
| 523 | VAN (sepsis) | 9.1 | 9.8 | 1.1 |
| 523 | VAN (undiagnosed) | 5.2 | 8.5 | 1.7 |
| 523 | VAN (pneumonia) | 11.7 | 19.5 | 1.8 |
| 523 | VAN (meningitis) | 0 | 1.2 | 1.9 |
| 523 | VAN (IAI) | 1.3 | 2.4 | 1.9 |
| 523 | VAN (C. diff) | 0 | 2.4 | 3.8 |
| 70 | VAN, TEC | 11 | 12.3 | 1.1 |
| 335 | VRC | 5 | 0 | 0.2 |
| 471 | VRC | 9.1 | 6.6 | 0.7 |
| 253 | BLAC (at discharge) | 1.6 | 3.2 | 2.1 |
| 140* | BLAC | 32.4 | 70 | 4.9 |
| 600 | BLAC, SXT | 27.5 | 16.3 | 0.5 |
| 600* | BLAC, SXT | 19.6 | 44.2 | 3.2 |



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.04.23284191>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



| ID | Type of diagnostic/ procedure | % patients receiving test/procedure | | OR |
|-------|----------------------------------|--|------|------|
| | | Pre | Post | |
| 507** | Documented exam | 52.7 | 95.6 | 19.7 |
| 507** | Documented exam | 52.7 | 95.6 | 19.7 |
| 382* | Blood culture | 91.9 | 98.5 | 5.9 |
| 4** | Culture | 14 | 45 | 5.4 |
| 523 | Blood culture | 89.6 | 97.6 | 4.6 |
| 146* | AST | 67.1 | 90.4 | 4.6 |
| 582* | Echocardiogram | 65.9 | 88.6 | 4 |
| 321** | Echocardiogram | 25.5 | 54.8 | 3.5 |
| 146* | Culture, AST | 42.5 | 69.2 | 3 |
| 140 | Urinary anitgen | 18.9 | 40.6 | 2.9 |
| 146* | Diagnostic work-up | 50.7 | 75 | 2.9 |
| 321* | Repeat blood culture | 79.8 | 89.6 | 2.2 |
| 335 | Repeat blood culture | 97.6 | 100 | 2 |
| 140 | Legionalla antigen | 18.9 | 31.3 | 1.9 |
| 140 | Sputum culture | 18.9 | 31.3 | 1.9 |
| 368 | Culture, AST | 1.3 | 2.3 | 1.8 |
| 523 | Urinalysis | 29.9 | 41.5 | 1.7 |
| 523 | Renal function test | 83.1 | 89. | 1.6 |
| 145** | Culture | 14.8 | 22.1 | 1.6 |
| 145** | Radiology | 60.3 | 68.3 | 1.4 |
| 145** | X-ray | 61.3 | 68.6 | 1.4 |
| 368 | Culture, AST | 7.4 | 7.9 | 1.1 |
| 129 | Blood culture | 32.2 | 33 | 1 |
| 145 | X-ray | 91.3 | 91.5 | 1 |
| 246 | Microbiology | 28.8 | 28.6 | 1 |
| 229 | Culture | 76.5 | 74.1 | 0.9 |
| 527 | Positive blood cultures | 12.8 | 9.8 | 0.7 |
| 129 | Culture | 87.9 | 83 | 0.7 |
| 140 | Blood culture | 73 | 62.5 | 0.6 |
| 419 | Urine culture | 7.5 | 4.4 | 0.6 |
| 419 | Tracheal culture | 3 | 1.5 | 0.5 |
| 600* | Repeat blood culture | 66.7 | 44.2 | 0.4 |
| 407** | Blood culture within 72 hours | 90.9 | 68.8 | 0.2 |
| 419** | Blood culture | 23.9, 6 | 4.4 | 0.1 |
| 6** | IV to PO conversion | 67 | 97 | 15.3 |
| 6** | IV to PO conversion | 34.8 | 62.7 | 3.2 |
| 129* | IV to PO conversion | 6 | 15 | 2.8 |
| 190 | IV to PO conversion | 1.6 | 3 | 2 |

